Social Media Press Releases
RSSShowing Press Releases with Tag: influenza virus
9/29/2006
MedImmune Named One of Maryland’s Fastest Growing Technology Companies in Deloitte Technology Fast 50 Program
» read more8/14/2006
MedImmune Replies to FDA’s Complete Response Letter for New Formulation of FluMist®
» read more7/31/2006
MedImmune Submits Refrigerator-Stable Formulation of FluMist® to FDA for Approval in Younger Children
» read more7/18/2006
MedImmune Receives Complete Response Letter From FDA for New Formulation of FluMist®
» read more7/06/2006
MedImmune Receives FDA Approval to Use Reverse Genetics Technology for FluMist® Vaccine Production
» read more6/29/2006
MedImmune Broadens Efforts to Develop Vaccines to Help Prevent RSV and Other Important Pediatric Respiratory Diseases
» read more6/15/2006
MedImmune and National Institutes of Health Begin Clinical Testing of a Live, Attenuated Intranasal Vaccine Against an H5N1 Avian Influenza Virus
» read more5/04/2006
MedImmune Awarded $170 Million, Five-Year Contract From U.S. Health and Human Services to Develop Cell-Based Influenza Vaccines
» read more5/01/2006
Phase 3 Study Results of MedImmune’s Next-Generation Influenza Vaccine Suggest Better Relative Efficacy Against Matched and Mismatched Strains Compared to the Flu Shot in Young Children
» read more5/01/2006
MedImmune Presents New Data From Pediatric Studies With FluMist(R) At Pediatric Academic Societies Annual Meeting
» read more4/03/2006
